How a personalised cancer vaccine could cut risk of death by half
A new study revealed that the personalised cancer vaccine intismeran, combined with Keytruda, reduced the risk of death from skin cancer recurrence by 49% and from its spread by 59%. Developed by Merck and Moderna, this Phase 3 trial marks a significant advancement in cancer treatment, potentially transforming patient care in India.